Gates Foundation Strategic Investment Fund Logo
Share this page:

Endpoints: Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study

By John Carrol

October 5, 2017

At the time Visterra made a bid early this year to go public, the timing was off. The boom of 2014 was long gone and the current bumper crop of IPOs had yet to develop. So now they’ve topped up their C round and closed it with $46.7 million in venture cash — enough to steer their lead program through a Phase IIb while getting another therapy through Phase I.

Read the full text here.